contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inbjudan-till-presentation-av-bioarctics-rapport-for-fjarde-kvartalet-oktober-december-2025-den-18-februari-klockan-930

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.

Brand new Q2 / 2025 below.            bioarctic.com              wkr0006-146.pdf    1682.08 KB

If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually been developed, tested, and brought to market for the first of these three. Decades of development work are turning into positive cash flow as of this writing, with marketing authorizations for the drug obtained in the USA in 2023, and subsequently in Japan and China for early-stage Alzheimer’s. The drug does not cure Alzheimer’s, but “only” stops its progression, but it is likely one of the only effective drugs for this disease now and in the near future, so the market should be guaranteed. In addition, there is the Parkinson’s drug Exidavnemab in the pipeline, which is currently only in phase 2a. Furthermore, the company is indeed developing a drug to prevent ALS, so BioArctic certainly cannot be accused of a lack of ambition. For an investor, this company is already at this stage a good cash flow generating company, whose pipeline brings nice additional options for a long-term investor. The 2025 figures look strong in terms of both earnings and cash flow, and at least the risk of dilution seems small at this stage. The company should now be able to stand on its own, and the valuation looks very moderate. In addition, foreign (non-Swedish) investors have a very small ownership stake, so if its reputation starts to spread outside Sweden, this could be an interesting time for an investment. Of course, it must always be kept in mind that there are risks in this investment as well, for example, if unexpected side effects suddenly appear in the drugs despite all tests. Nevertheless, I believe that with BioArctic, an investor can get involved in good cash flow with reasonable risk, and at the same time, get to follow a remarkably interesting pharmaceutical company.

BioArctic

Stockholm den 11 februari 2026 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publicerar bolagets rapport för fjärde kvartalet, perioden oktober - december 2025, onsdagen den 18 februari 2026...

<div class="abstract">Stockholm den 11 februari 2026 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publicerar bolagets rapport för fjärde kvartalet, perioden oktober - december 2025, onsdagen den 18 februari 2026, klockan 08:00 (CET).</div>I anslutning till rapporten bjuder BioArctic in investerare, analytiker och media till en ljudsändning med telefonkonferens (på engelska) den 18 februari, klockan 09:30 (CET), då vd Gunilla Osswald och CFO Anders Martin-Löf, tillsammans med kollegor, kommer att presentera och kommentera rapporten för det fjärde kvartalet. Presentationen följs av en frågestund.&nbsp;Om du önskar delta via webbsändning, vänligen använd nedanstående länk. Via webbsändningen finns möjlighet att ställa skriftliga frågor.Webbsändning: <a href="https://bioarctic.events.inderes.com/q4-report-2025/register">https://bioarctic.events.inderes.com/q4-report-2025/register</a>&nbsp;Om du önskar ställa muntliga frågor i samband med presentationen, vänligen registrera dig via länken nedan. Efter registreringen får du telefonnummer och ett konferens-ID för att logga in till konferensen. Via telefonkonferensen finns möjlighet att ställa muntliga frågor.<a href="https://events.inderes.com/bioarctic/q4-report-2025/dial-in">https://events.inderes.com/bioarctic/q4-report-2025/dial-in</a>&nbsp;Webbsändningen kan även ses i efterhand och nås på BioArctics webbplats.<a href="https://www.bioarctic.com/sv/investerare/finansiella-rapporter-och-presentationer/">https://www.bioarctic.com/sv/investerare/finansiella-rapporter-och-presentationer/&nbsp; </a>&nbsp;---&nbsp;För ytterligare information vänligen kontakta: Oskar Bosson, VP Communications and Investor Relations E-post: <a href="mailto:oskar.bosson@bioarctic.com">oskar.bosson@bioarctic.com</a>&nbsp; Tel: 0704-10 71 80&nbsp;Jenny Ljunggren, External Communications and Investor Relations Manager E-post: <a href="mailto:jenny.ljunggren@bioarctic.com">jenny.ljunggren@bioarctic.com</a> Tel: 076 013 86 08&nbsp;Informationen lämnades för offentliggörande den 11 februari 2026, kl. 08.30 (CET).&nbsp;Om BioArctic AB&nbsp;BioArctic AB (publ) är ett svenskt forskningsbaserat biofarmabolag med fokus på innovation av läkemedel som kan fördröja eller stoppa sjukdomsförloppet av neurodegenerativa sjukdomar. Företaget ligger bakom lecanemab (Leqembi®) - världens första läkemedel som bevisat bromsar sjukdomsutvecklingen och minskar den kognitiva försämringen vid tidig Alzheimers sjukdom. Lecanemab har utvecklats i samarbete med BioArctics partner Eisai, som ansvarar för kommersialisering och regulatoriska processer globalt. Utöver lecanemab har BioArctic en bred forskningsportfölj med antikroppar mot Parkinsons sjukdom och ALS samt ytterligare projekt mot Alzheimers sjukdom. Flera av projekten utnyttjar bolagets egenutvecklade teknologiplattform BrainTransporter™ som hjälper till att förbättra transporten av antikroppar in i hjärnan. BioArctics B-aktie (BIOA B) är noterad på Nasdaq Stockholm Large Cap. För ytterligare information, besök www.bioarctic.com.&nbsp;<div></div>